Trial Profile
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary) ; Voriconazole (Primary) ; Voriconazole (Primary)
- Indications Invasive bronchopulmonary aspergillosis
- Focus Adverse reactions
- Acronyms SCYNERGIA
- Sponsors SCYNEXIS
- 28 Mar 2024 According to a SCYNEXIS media release, final study reports from FURI, CARES, SCYNERGIA, NATURE, and VANQUISH studies are anticipated to be delivered to GSK in the first half of 2024, which would trigger a $10 million development milestone payment to SCYNEXIS.
- 23 Jun 2023 Status changed from active, no longer recruiting to completed.
- 23 Jun 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.